Tokunaga Yukihiko, Sasaki Hirokazu, Ohnishi Takanori
Department of Surgery, Osaka North Japan Post Hospital, Osaka, Japan.
Hepatogastroenterology. 2010 Nov-Dec;57(104):1390-4.
BACKGROUND/AIMS: In colorectal cancer (CRC), 5-fluorouracil (5-FU) has been a basic chemotherapeutic agent. Antitumor effects of 5-FU and its derivatives are likely due to inter-individual difference in the drug sensitivity.
We evaluated the 5-FU sensitivity of cancer cells from CRC patients using the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) under multiple drug concentration and contact durations. The area under the concentration curve (AUC) and growth inhibition curve (IR) were combined in the AUC-IR curve. Using the AUC-IR curve, the individual AUC(IR50) was calculated. Furthermore, using the AUC values of 5-FU during 24 hours with chemotherapy with UFT and S-1, the durations to achieve the AUC(IR50) were calculated in chemotherapy with UFT or S-1 for individual patient.
The value of individual AUC(IR50) ranged widely from less than 100 microg hr/ml to more than 1000 microg hr/ml. Approximately 13% of patients demonstrated a relatively low 5-FU sensitivity. Durations of chemotherapy to achieve the AUC(IR50) differed widely depending on the AUC(IR50) of individual patient. Relapse free survival was significantly better in the patients who have achieved individual AUC(IR50) than those who have not achieved the AUC(IR50).
The present results suggest that the antitumor effects of 5-FU and its derivatives differ widely depending on inter-individual difference of sensitivity, and that individual AUC(IR50) may be useful to predict the optimal duration of chemotherapy.
背景/目的:在结直肠癌(CRC)中,5-氟尿嘧啶(5-FU)一直是一种基础化疗药物。5-FU及其衍生物的抗肿瘤作用可能归因于个体对药物敏感性的差异。
我们使用胶原凝胶液滴包埋培养-药物敏感性试验(CD-DST),在多种药物浓度和接触时间条件下,评估了CRC患者癌细胞对5-FU的敏感性。浓度曲线下面积(AUC)和生长抑制曲线(IR)合并在AUC-IR曲线中。利用AUC-IR曲线,计算个体AUC(IR50)。此外,使用UFT和S-1化疗24小时期间5-FU的AUC值,计算个体患者在UFT或S-1化疗中达到AUC(IR50)的持续时间。
个体AUC(IR50)值范围广泛,从小于100微克·小时/毫升到大于1000微克·小时/毫升。约13%的患者表现出相对较低的5-FU敏感性。达到AUC(IR50)的化疗持续时间因个体患者的AUC(IR50)不同而有很大差异。达到个体AUC(IR50)的患者无复发生存期明显优于未达到AUC(IR50)的患者。
目前的结果表明,5-FU及其衍生物的抗肿瘤作用因个体敏感性差异而有很大不同,个体AUC(IR50)可能有助于预测化疗的最佳持续时间。